Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

  • Paul D Carey1Email author,

    Affiliated with

    • Bavanisha Vythilingum1,

      Affiliated with

      • Soraya Seedat1,

        Affiliated with

        • Jacqueline E Muller1,

          Affiliated with

          • Michael van Ameringen2 and

            Affiliated with

            • Dan J Stein1

              Affiliated with

              BMC Psychiatry20055:44

              DOI: 10.1186/1471-244X-5-44

              Received: 25 November 2005

              Accepted: 30 November 2005

              Published: 30 November 2005

               

              The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2].

              Authors’ Affiliations

              (1)
              MRC Research Unit on Anxiety Disorders, University of Stellenbosch
              (2)
              Department of Psychiatry and Behavioral Neurosciences, McMaster University

              References

              1. Carey PD, Vythilingum B, Seedat S, Muller JE, van AM, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 2005, 5: 5.View ArticlePubMed
              2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68: 29–39.View ArticlePubMed
              3. Pre-publication history

                1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-244X/​5/​44/​prepub

              Copyright

              © Carey et al. 2005

              This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

              Advertisement